| Jeffrey Gilligan, MD | |
|
33 Hospital Ave., Danbury, CT 06810 | |
| (203) 792-2003 | |
| (203) 739-8926 |
| Full Name | Jeffrey Gilligan |
|---|---|
| Gender | Male |
| Speciality | Neurological Surgery |
| Location | 33 Hospital Ave., Danbury, Connecticut |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073909024 | NPI | - | NPPES |
| Entity Name | Danbury Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548293343 PECOS PAC ID: 1557273935 Enrollment ID: O20031104000476 |
News Archive
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the Southern District of Indiana has issued a decision invalidating two patents listed in the FDA's Orange Book for Eli Lilly's Evista® (raloxifene hydrochloride) Tablets in litigation concerning Teva's abbreviated new drug application to market a generic version. The court found these patents to be invalid for lack of written description.
Dainippon Sumitomo Pharma Co., Ltd. ("DSP") and Sepracor Inc. ("Sepracor") (NASDAQ: SEPR) today announce the successful completion of the tender offer by DSP's indirect wholly-owned subsidiary, Aptiom, Inc. ("Offeror"), to acquire all outstanding shares of common stock of Sepracor for $23.00 per share in cash.
The Los Angeles Times reports on San Francisco's public option: "Over the last two years, three-quarters of San Francisco's uninsured adults have enrolled in a public program that guarantees access to medical services, an effort that is being touted as a national model during the rancorous debate over healthcare reform.
Today Merck announced that Health Canada has approved the new intravenous formulation of EMEND IV. Used in combination with a 5-HT3 antagonist class of antiemetics and dexamethasone, fosaprepitant dimeglumine is indicated for the prevention of acute and delayed nausea and vomiting due to highly emetogenic cancer chemotherapy.
› Verified 5 days ago
| Entity Name | Nuvance Health Medical Practice Ct Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407898117 PECOS PAC ID: 4789597691 Enrollment ID: O20031205000130 |
News Archive
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the Southern District of Indiana has issued a decision invalidating two patents listed in the FDA's Orange Book for Eli Lilly's Evista® (raloxifene hydrochloride) Tablets in litigation concerning Teva's abbreviated new drug application to market a generic version. The court found these patents to be invalid for lack of written description.
Dainippon Sumitomo Pharma Co., Ltd. ("DSP") and Sepracor Inc. ("Sepracor") (NASDAQ: SEPR) today announce the successful completion of the tender offer by DSP's indirect wholly-owned subsidiary, Aptiom, Inc. ("Offeror"), to acquire all outstanding shares of common stock of Sepracor for $23.00 per share in cash.
The Los Angeles Times reports on San Francisco's public option: "Over the last two years, three-quarters of San Francisco's uninsured adults have enrolled in a public program that guarantees access to medical services, an effort that is being touted as a national model during the rancorous debate over healthcare reform.
Today Merck announced that Health Canada has approved the new intravenous formulation of EMEND IV. Used in combination with a 5-HT3 antagonist class of antiemetics and dexamethasone, fosaprepitant dimeglumine is indicated for the prevention of acute and delayed nausea and vomiting due to highly emetogenic cancer chemotherapy.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeffrey Gilligan, MD 33 Hospital Ave., Danbury, CT 06810 Ph: (203) 792-2003 | Jeffrey Gilligan, MD 33 Hospital Ave., Danbury, CT 06810 Ph: (203) 792-2003 |
News Archive
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the Southern District of Indiana has issued a decision invalidating two patents listed in the FDA's Orange Book for Eli Lilly's Evista® (raloxifene hydrochloride) Tablets in litigation concerning Teva's abbreviated new drug application to market a generic version. The court found these patents to be invalid for lack of written description.
Dainippon Sumitomo Pharma Co., Ltd. ("DSP") and Sepracor Inc. ("Sepracor") (NASDAQ: SEPR) today announce the successful completion of the tender offer by DSP's indirect wholly-owned subsidiary, Aptiom, Inc. ("Offeror"), to acquire all outstanding shares of common stock of Sepracor for $23.00 per share in cash.
The Los Angeles Times reports on San Francisco's public option: "Over the last two years, three-quarters of San Francisco's uninsured adults have enrolled in a public program that guarantees access to medical services, an effort that is being touted as a national model during the rancorous debate over healthcare reform.
Today Merck announced that Health Canada has approved the new intravenous formulation of EMEND IV. Used in combination with a 5-HT3 antagonist class of antiemetics and dexamethasone, fosaprepitant dimeglumine is indicated for the prevention of acute and delayed nausea and vomiting due to highly emetogenic cancer chemotherapy.
› Verified 5 days ago
Dr. Ramon A Batson, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 33 Hospital Ave., Danbury, CT 06810 Phone: 203-792-2003 Fax: 203-739-8926 | |
Dr. Joshua D Marcus, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 33 Hospital Ave., Danbury, CT 06810 Phone: 203-792-2003 Fax: 203-739-8926 | |
Scott P Sanderson, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 33 Hospital Ave., Danbury, CT 06810 Phone: 203-792-2003 Fax: 203-739-8926 |